Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lyophilized sterile fecal filtrate
- Development stage
- Phase 2
- Lead developer
- University of Alberta
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lyophilized sterile fecal filtrate (LSFF) is a processed form of fecal material that has been filtered to remove live bacteria and then freeze-dried (lyophilized). It was developed as a potential alternative to traditional fecal microbiota transplantation (FMT) for treating recurrent Clostridioides difficile infection (rCDI). Unlike standard FMT, LSFF does not contain live microbes, which was hypothesized to potentially offer safety advantages while still providing therapeutic benefits. However, clinical trials have shown LSFF to be inferior to lyophilized FMT (LFMT) in preventing recurrent C. difficile infection, suggesting that live microbes play a crucial role in the efficacy of fecal transplant therapies.
- Other names
- Sterile stool filtratefecal filtrate-University of Pecs-Clostridioides difficile infection
Beyond the preview
Go deeper on lyophilized sterile fecal filtrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lyophilized sterile fecal filtrate.